X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs SUN PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA SUN PHARMA ABBOTT INDIA/
SUN PHARMA
 
P/E (TTM) x 37.8 28.1 134.6% View Chart
P/BV x 9.8 3.0 330.0% View Chart
Dividend Yield % 0.7 0.4 165.6%  

Financials

 ABBOTT INDIA   SUN PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
SUN PHARMA
Mar-18
ABBOTT INDIA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs6,110701 872.2%   
Low Rs3,996433 922.4%   
Sales per share (Unadj.) Rs1,552.2110.4 1,405.9%  
Earnings per share (Unadj.) Rs188.811.0 1,719.9%  
Cash flow per share (Unadj.) Rs196.417.2 1,140.1%  
Dividends per share (Unadj.) Rs55.002.00 2,750.0%  
Dividend yield (eoy) %1.10.4 308.5%  
Book value per share (Unadj.) Rs796.6158.8 501.6%  
Shares outstanding (eoy) m21.252,399.26 0.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.35.1 63.4%   
Avg P/E ratio x26.851.6 51.8%  
P/CF ratio (eoy) x25.732.9 78.2%  
Price / Book Value ratio x6.33.6 177.7%  
Dividend payout %29.118.2 159.9%   
Avg Mkt Cap Rs m107,3761,360,021 7.9%   
No. of employees `0003.317.8 18.7%   
Total wages/salary Rs m3,93753,671 7.3%   
Avg. sales/employee Rs Th9,929.314,890.9 66.7%   
Avg. wages/employee Rs Th1,185.13,017.1 39.3%   
Avg. net profit/employee Rs Th1,207.71,480.6 81.6%   
INCOME DATA
Net Sales Rs m32,985264,895 12.5%  
Other income Rs m1,1708,388 13.9%   
Total revenues Rs m34,155273,282 12.5%   
Gross profit Rs m5,24556,081 9.4%  
Depreciation Rs m16214,998 1.1%   
Interest Rs m385,176 0.7%   
Profit before tax Rs m6,21544,295 14.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m2,2038,452 26.1%   
Profit after tax Rs m4,01226,338 15.2%  
Gross profit margin %15.921.2 75.1%  
Effective tax rate %35.419.1 185.7%   
Net profit margin %12.29.9 122.3%  
BALANCE SHEET DATA
Current assets Rs m22,655316,359 7.2%   
Current liabilities Rs m6,681198,643 3.4%   
Net working cap to sales %48.444.4 109.0%  
Current ratio x3.41.6 212.9%  
Inventory Days Days6595 68.3%  
Debtors Days Days29108 27.1%  
Net fixed assets Rs m835213,178 0.4%   
Share capital Rs m2132,399 8.9%   
"Free" reserves Rs m16,715378,606 4.4%   
Net worth Rs m16,928381,006 4.4%   
Long term debt Rs m017,721 0.0%   
Total assets Rs m24,162643,028 3.8%  
Interest coverage x163.79.6 1,712.6%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.40.4 331.4%   
Return on assets %16.84.9 342.0%  
Return on equity %23.76.9 342.9%  
Return on capital %36.910.0 368.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36940,816 0.9%   
Fx outflow Rs m3,80730,143 12.6%   
Net fx Rs m-3,43810,673 -32.2%   
CASH FLOW
From Operations Rs m1,52739,072 3.9%  
From Investments Rs m-2,148-33,708 6.4%  
From Financial Activity Rs m-1,024-15,393 6.7%  
Net Cashflow Rs m-1,646-7,359 22.4%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 5.1 154.0%  
FIIs % 0.1 23.0 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 8.3 206.0%  
Shareholders   18,270 133,026 13.7%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  STERLING BIOTECH  CADILA HEALTHCARE  VENUS REMEDIES  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Lower; Banking and Automobile Stocks Witness Selling(Closing)

After opening the day on a strong note, Indian share markets witnessed selling pressure during closing hours and ended their trading session marginally lower.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Apr 23, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - ELDER PHARMA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS